Broncolin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Broncolin

Broncolin is a pharmaceutical product whose single active ingredient is the synthetic compound Salbutamol, which is internationally recognized by the International Nonproprietary Name (INN) system. It is fundamentally classified as a Bronchodilator, a type of medicine specifically used to quickly widen the air passages in the lungs.


Property Description
Active ingredient Salbutamol (Albuterol)
Primary Form Inhalation (MDI, Nebulizer Solution)
Pharmacological Class Bronchodilator (SABA)
General Purpose Rapid relief of airway constriction
Origin Synthetic compound

1. Defining Broncolin: Core Ingredient and Pharmacological Class

Broncolin is an effective Bronchodilator that contains the active ingredient, Salbutamol, a synthetic compound also known as Albuterol in the United States. This compound is categorized as a Short-Acting beta2-Adrenoceptor Agonist (SABA), a precise term confirming its mechanism is to stimulate specific receptors in the airway muscles to promote relaxation. This pharmacological classification is widely recognized, and Salbutamol is included on essential medicine lists for the treatment of respiratory conditions. This medicine is considered crucial for providing timely, rapid-acting relief for those experiencing acute breathing difficulties.

2. Forms, Administration Types, and Origin

This medicine is provided in several distinct dosage forms, allowing for both local and systemic delivery. These forms include an oral syrup or tablets, as well as preparations intended for inhalation, such as a solution for nebulization or a pressurized Metered-Dose Inhaler (MDI). The administration of the active ingredient is thus achieved through either the oral route or inhalation. Salbutamol's primary function is to relieve airway obstruction. This highlights the drug's established role in swiftly improving air flow to the lungs, a benefit that makes it a tool for use in scenarios like an unexpected onset of chest tightness. Broncolin is a single-component product whose effects are derived exclusively from its synthetic active ingredient, Salbutamol, suspended in an appropriate aqueous base or excipients depending on the final dosage form.

3. General Purpose: The Benefit of Airway Relaxation

The general therapeutic purpose of Broncolin is to provide rapid relief from the acute symptoms of airway constriction, such as sudden shortness of breath or the feeling of chest tightness. Its core function is achieved by causing smooth muscle relaxation within the bronchial tubes, which physically opens the passages and significantly improves airflow. This fast-acting benefit is intended for restoring normal breathing function when the airways suddenly narrow.

Regulatory References

  1. WHO Model List of Essential Medicines
  2. Comprehensive medical resources confirm that Salbutamol's primary function is to relieve airway obstruction

What side effects are possible with Broncolin?

Possible side effects and safety information

The safety profile for Broncolin, which contains Salbutamol (Albuterol), is derived from official regulatory classifications of observed adverse reactions. These effects are organized by frequency and the body system affected, with the most common reactions related to the drug’s stimulating effect.


Frequency-Classified Adverse Reactions

Adverse reactions are classified according to regulatory standards:

  • Very Common: Tremor.
  • Common: Headache, Tachycardia (increased heart rate), Palpitations, and Muscle cramps.
  • Uncommon: Mouth and throat irritation (mainly with inhalation forms).
  • Rare: Hypokalaemia (low potassium levels) and Peripheral vasodilatation.
  • Very Rare: Paradoxical bronchospasm, Hypersensitivity reactions (such as angioedema or urticaria), Cardiac arrhythmias, and Myocardial ischaemia.

The most frequent effects, such as tremor and headache, are typically associated with initial exposure and may disappear with continued use. However, potentially serious metabolic changes, including hypokalaemia and elevated blood glucose levels, are noted in regulatory documents, particularly with high-dose or long-term systemic exposure.


Safety Considerations and Restrictions

The official labeling notes that the medicine can produce clinically significant cardiovascular effects, which warrants caution in specific patient groups, including those with pre-existing coronary insufficiency, arrhythmias, or hypertension. Very rare but critical events, such as paradoxical bronchospasm—an immediate and life-threatening worsening of breathing after use—are explicitly documented. Additionally, the label records specific safety notes for the pediatric population, including reports of hyperactivity.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Broncolin (Salbutamol/Albuterol) is associated with exaggerated effects on the cardiovascular and metabolic systems, which regulatory authorities identify as potentially severe. In any suspected overdose situation, the patient or caregiver must seek emergency medical attention immediately or contact the Poison Help line.

Documented Clinical and Physiological Manifestations

Overdose may present with common signs of excessive sympathetic stimulation, including tachycardia (rapid heart rate), palpitations, and physical tremor. More severe presentations documented in regulatory information include serious cardiac arrhythmias, myocardial ischaemia, and metabolic disturbances. These metabolic disturbances consist of abnormally low blood potassium (hypokalaemia), a buildup of lactic acidosis, and high blood glucose (hyperglycaemia). Nausea and vomiting are often noted, especially in cases of oral ingestion or overdose in children.

Required Supportive Management

Treatment for Salbutamol overdose is defined by regulatory authorities as symptomatic and supportive. Intervention includes monitoring serum potassium levels and serum lactate to manage the potential for severe hypokalaemia and metabolic acidosis. While no specific antidote is available, cardio-selective beta-blocking agents may be considered for severe cardiac symptoms; however, this approach requires specialized caution due to the risk of precipitating bronchospasm.

Therapeutic Uses of Broncolin

What Broncolin Treats: Main Uses and Benefits

Broncolin, containing the active ingredient Salbutamol, is used in situations involving certain distressing symptoms related to the narrowing of the airways. This medication is indicated for managing symptoms related to bronchospasm in patients with reversible obstructive airway disease, such as Asthma and COPD.


Treating Sudden Airflow Restriction in Asthma and COPD

This medication is applied in clinical settings that involve acute or unstable symptom patterns, specifically addressing the sudden, muscular tightening of the airways. It is commonly used across conditions characterized by periods of heightened symptoms like asthma and COPD. The medication supports the patient during difficult episodes by easing distress and may help improve day-to-day comfort during symptomatic periods.


Managing Wheezing, Chest Tightness, and Coughing

Broncolin is relevant for managing symptoms that interfere with daily comfort such as audible wheezing, the feeling of chest tightness, and acute, disruptive shortness of breath. It is generally used when groups of symptoms appear suddenly or fluctuate. The primary benefit is offering symptomatic relief that helps patients cope more steadily, providing support that helps ease the overall symptom load.


Supportive Relief for Trigger-Induced Symptoms

This medication is also relevant when supportive symptom management is appropriate before exposure to known triggers, particularly for exercise-induced bronchoconstriction or anticipated allergen exposure. Applied in scenarios where additional management of discomfort is required, this use may assist with managing anticipated symptoms and supports the patient during episodes of heightened discomfort.

Quick Fact: Relief for Acute Bronchospasm
Broncolin supports patients during episodes of sudden airway constriction, particularly those associated with Asthma, COPD, and exercise-induced breathing difficulties.

Regulatory References

  1. U.S. Food and Drug Administration (FDA) on Albuterol Sulfate Inhalation Aerosol

Eligibility and Restrictions for Use

The eligibility for using Broncolin, which contains the active ingredient Salbutamol (Albuterol), is strictly defined by regulatory label information, encompassing age, pre-existing conditions, and known sensitivities.

Populations for Whom Use is Approved

Use is approved for adults and adolescents (12 years and older) for the treatment and prevention of bronchospasm. For inhalation forms, use is also permitted for children aged 4 years and older.

Contraindications and Age Restrictions

Classification Eligibility Rule (Official Labeling)
Absolute Non-Eligibility Patients with a documented hypersensitivity (allergy) to Salbutamol or any component of the specific formulation, including known milk protein allergy for certain excipient-containing inhalers.
Age Not Established Safety and effectiveness for inhalation aerosol are not established by the FDA for children under 4 years of age.

Conditional Use and Restrictions

Official labeling mandates caution for several patient groups due to potential risks: those with cardiovascular disorders (e.g., hypertension, cardiac arrhythmias), hyperthyroidism, diabetes mellitus, and convulsive disorders. In terms of physiological states, use during pregnancy and lactation is advised only when the potential benefit to the mother outweighs the potential risk to the neonate, as documented by regulators.

What should I know about interactions with other medicines?

The official regulatory information for Broncolin (Salbutamol/Albuterol) details specific interaction patterns with other medicinal products, primarily involving opposing pharmacodynamic effects, additive risks, and altered drug exposure.

Restricted and High-Risk Combinations

The co-administration of Non-selective Beta-blockers is officially restricted, as these agents inhibit the bronchodilator action of Salbutamol and carry a regulatory risk of severe bronchospasm. Concomitant use with other Sympathomimetic Agents, including other aerosol bronchodilators, is generally not recommended due to the potential for additive cardiovascular effects. Official caution is mandatory when co-administering with Monoamine Oxidase Inhibitors (MAOIs) or Tricyclic Antidepressants (TCAs), as these may potentiate the effect of Salbutamol on the vascular system; this risk is officially noted to persist for 2 weeks following the discontinuation of the MAOI or TCA.

Pharmacodynamic and Exposure Interactions

Co-administration with Non-Potassium-Sparing Diuretics, Xanthine Derivatives, and Corticosteroids is associated with an official potentiation of hypokalemia (low serum potassium). Regulatory documentation also notes that Salbutamol administration may result in a mean decrease in serum Digoxin levels. Specific population cautions exist for patients with Renal Impairment, where effects may be increased due to slower clearance, and for patients with pre-existing Diabetes Mellitus, where effects may aggravate the condition. The official profile further notes that the safety and interaction profiles of herbal products and supplements have not been established.

Mechanism of Action

Selective beta2-Receptor Agonism and Airway Muscle Control

The core action of Broncolin (Salbutamol) is based on highly specific pharmacodynamic mechanisms that target the key regulatory systems within the airways, which results from the rapid kinetics of the G s protein signaling cascade.

This mechanism covers the molecular interaction where the drug binds to and activates beta2-adrenergic receptors (beta2-ARs), a type of G protein-coupled receptor found on the smooth muscle cells surrounding the air passages. The resulting activation initiates an intracellular cascade, which effectively leads to the relaxation of the bronchial smooth muscle tissue.

Intracellular cAMP Cascades and Calcium Regulation

The activation of the beta2-AR stimulates the enzyme adenylyl cyclase, rapidly increasing the second messenger cyclic adenosine monophosphate ( cAMP) inside the cell. This cascade directly modifies the regulation of intracellular calcium ion ( Ca^2+) levels by promoting its sequestration, thereby reducing the concentration necessary for muscle contraction. The reduction in muscle-contracting Ca^2+ concentration is the direct step that causes the widening of the air passages (bronchodilation), a primary physiological effect. However, this mechanism is subject to receptor desensitization with frequent use, which physiologically results in the desensitization and potential downregulation of the beta2-ARs.

Dosage and Administration Information

The usage of the medicine, which contains Salbutamol (Albuterol), is based on the intended purpose and dosage form. Routes of administration include inhalation (via metered-dose inhalers or nebulizers), which is typical for intermittent, short-term use, and oral delivery (syrup or tablets) for systemic administration. Parenteral routes (IV, IM, SC) are generally restricted to supervised clinical settings.

For acute symptom relief via the metered-dose inhaler, the standard adult dose is 100 mcg to 200 mcg (one to two inhalations), administered every four to six hours as needed (PRN). To prevent symptoms caused by known triggers, two inhalations are taken 15 to 30 minutes before the anticipated activity. The total dose for acute relief should generally not exceed eight inhalations in a 24-hour period, unless directed otherwise by a healthcare professional.

Correct administration requires specific procedural steps. Metered-dose inhalers must be primed with a specific number of sprays before first use or after a period of non-use. Furthermore, the inhaler actuator must be cleaned at least once a week to ensure accurate dose delivery. Oral dosage forms may be swallowed with or without food. Dosing for specific populations, such as older adults, often starts at a lower daily amount (e.g., 2 mg tablets, three to four times a day).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Broncolin

Evidence for Use in Acute Bronchospasm in Asthma

The research exploring Broncolin's active compound has primarily focused on its use in conditions characterized by fluctuating or episodic manifestations, particularly outcomes related to physiological strain associated with asthma. The available evidence comes from short-term Randomized Controlled Trials (RCTs) and Systematic Reviews.

Researchers examined outcomes related to physiological strain such as measurements of air flow ( FEV1 and PEF) and also applied in studies examining patient-reported experiences of wheezing and shortness of breath. Studies report how air flow measures evolved in the observed populations over defined time intervals. Long-term outcomes related to the effects of frequent use on overall health patterns are not well characterized.

Evidence for Use in Acute Symptoms of COPD

The active compound in Broncolin was evaluated in studies relevant to exploring temporary physiological imbalance associated with Chronic Obstructive Pulmonary Disease (COPD). The research base includes clinical trials that focus on outcomes related to physiological strain including airflow restriction.

Research examined how the medication was observed in exploring shortness of breath (dyspnea) and its effect on lung function measures. Findings describe patterns that were measured during the study period, related to outcomes describing episodic or acute changes. Data are still emerging regarding the use of this compound for long-term management of COPD.

Evidence for Preventing Exercise-Induced Breathing Difficulties

The research related to preventing exercise-induced bronchoconstriction (EIB) primarily consists of controlled Crossover Studies. These studies examined how symptoms and air flow measures changed when the compound was observed in a single-dose treatment before a standardized exercise challenge.

Studies monitored outcomes describing episodic or acute changes, examining the post-exercise air flow measurements and changes observed during the study period. Research describes patterns where outcomes related to efficacy observed in trials were monitored during frequent or regular, non-acute use. The long-term effects are not fully established regarding the impact of repeated prophylactic use on airway sensitivity over many years.

Key Studies & References

  1. Albuterol Oral Inhalation: MedlinePlus Drug Information (National Library of Medicine)
  2. Label: ALBUTEROL SULFATE HFA- albuterol sulfate aerosol, metered (U.S. DailyMed / FDA Labeling)
  3. WHO Model List of Essential Medicines (EML) - Salbutamol entry (World Health Organization)
  4. Systematic Review: Safety of short-acting β2-agonists in patients with asthma (Example for 'frequent use' association)

Frequently Asked Questions (FAQ)

Common questions about Broncolin (FAQ)

Q: Is Broncolin considered a cough suppressant or an expectorant?

A: According to official drug classifications, the active ingredient in Broncolin is categorized as a Bronchodilator. Its primary function is to relax the smooth muscles surrounding the airways to improve airflow. This mechanism is distinct from the pharmacological actions of both cough suppressants, which target the cough reflex, and expectorants, which help loosen mucus.

Q: How long does it usually take for Broncolin to start working?

A: Official regulatory documents describe the active ingredient, Salbutamol, as providing rapid relief. Specifically, the onset of its effect following administration by inhalation is often observed within about five minutes.

Q: How long does the effect of Broncolin typically last?

A: Regulatory information indicates that the effects of the active ingredient are generally maintained for approximately four to six hours following administration. This duration of action is reflected in the official suggested dosing intervals.

Q: Is Broncolin safe to use for a long period of time?

A: Studies and official information have primarily focused on the use of Broncolin for short-term and acute relief. Long-term outcomes related to frequent or chronic use are generally described as not well characterized in regulatory documents. Regulatory documents indicate that increased reliance on the medicine is often noted as a potential sign of underlying changes in the condition.

Q: Can Broncolin be taken at the same time as cold and flu medicine?

A: Official documents caution against using Broncolin alongside certain types of medications known as sympathomimetic agents, which can be components of some over-the-counter cold and flu products. Official documentation advises caution regarding this combination due to the risk of additive cardiovascular effects.

Q: Does Broncolin interact with common vitamins or supplements?

A: The official product information notes that the safety and interaction profiles of most common supplements and herbal products have not been established through regulatory studies. This means there is limited official data available regarding these combinations.

Q: Is Broncolin known to interact with alcohol?

A: Patient guidance derived from regulatory resources generally indicates that the active ingredient in Broncolin is not known to interact with moderate consumption of alcohol.

Q: Does Broncolin have any warnings related to driving or operating machinery?

A: Because common side effects like tremor (shaking) and dizziness can occur, official patient information advises caution. Users should wait until they are aware of how the medicine affects them before engaging in such activities, as indicated in official documentation.

Q: Does Broncolin contain sugar or artificial sweeteners?

A: The presence of sugar or artificial sweeteners depends on the specific dosage form of Broncolin (e.g., solution, syrup, or tablet). The full list of inactive ingredients, or excipients, for the particular product version should be consulted in the official regulatory label.

Q: Are there any specific foods or drinks to avoid while using Broncolin?

A: Generally, patient guidance sourced from regulatory bodies indicates that a user may continue their normal diet while using the active ingredient in Broncolin. Specific food restrictions are not commonly listed in the official product information.

Q: What should I do if I forget to use Broncolin at the usual time?

A: Official patient instructions provide guidance on how to manage a missed oral dose. These instructions typically specify to avoid taking extra medication to make up for a missed dose and to consult the specific regulatory document for the product.

Q: Is there an age limit for who can use Broncolin?

A: For the inhalation aerosol form, use is officially approved for children aged 4 years and older. Regulatory bodies have not established the safety and effectiveness for children below this age.

Q: Can Broncolin affect the results of any lab tests?

A: Official research and drug information notes that using an inhaler can, for a short period after administration, potentially cause a false positive reading on some breath alcohol tests. Waiting a short period after use before taking such a test is typically noted in guidance.

Q: Is it normal to feel a tingling sensation after using Broncolin?

A: Tingling, or Paresthesia, is a type of neurological symptom. This sensation is occasionally noted in the regulatory listing of side effects for the active ingredient, categorized according to its documented frequency in clinical trials.

Q: What research themes have been examined for Broncolin?

A: The research on Broncolin has focused on its use for conditions characterized by airway constriction. These themes include: its role in managing acute bronchospasm in asthma, its use during acute symptoms of Chronic Obstructive Pulmonary Disease (COPD), and its ability to prevent exercise-induced breathing difficulties.

Q: Can I use Broncolin if I am lactose intolerant?

A: The relevance of lactose intolerance depends entirely on the specific product formulation. Some regulatory labels for certain dosage forms list lactose as an inactive ingredient (excipient), which is a factor for individuals with this condition.

Q: Can Broncolin be used for symptoms other than a cough?

A: The official therapeutic uses for Broncolin primarily relate to providing relief for symptoms of airway constriction. These symptoms typically include wheezing and sudden shortness of breath (dyspnea) associated with respiratory conditions.

Q: Does using Broncolin make me drowsy?

A: Drowsiness (somnolence) is typically listed in regulatory documents as an uncommon or rare side effect of the active ingredient. It is not generally described as a frequently expected outcome of its use.

Q: Are there specific instructions for what to do in case of an accidental overdose (purely factual information)?

A: Official regulatory labels indicate that an overdose can lead to severe adverse effects. The documentation notes that emergency medical assistance or contacting a Poison Control service should be considered in such a situation.

Q: What are the official guidelines regarding use of Broncolin with other over-the-counter drugs?

A: Official guidelines emphasize reviewing the interaction section for specific drug classes, such as sympathomimetic agents. They also caution that the safety profile with many general supplements or herbal products has not been fully established.

Q: Can Broncolin cause stomach upset?

A: Regulatory side effect listings for the active ingredient often include reports of gastrointestinal discomfort. These can include nausea and vomiting (stomach upset), which are classified as common or of incidence not known, depending on the source.

How should Broncolin be stored and disposed of?

How to Store and Dispose of Broncolin

Official regulatory information requires that Broncolin products be stored within a defined temperature range to maintain potency and stability. The labeled requirement is to store the product at controlled room temperature, typically between 15 C and 30 C (59 F and 86 F). Storage must avoid excessive heat at all times.

All medicines must be stored out of the reach of children to prevent accidental ingestion or misuse.

Regarding disposal, unused or expired Broncolin should be handled according to general governmental recommendations for non-controlled over-the-counter medicines. If a drug take-back program is unavailable, this typically involves mixing the medicine with an undesirable substance, placing the mixture in a sealed container, and discarding it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Broncolin found in:

A-Z Index: